A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Recruiting

Phase 2

Raludotatug DeruxtecanA Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06864169

Conditions

Gastrointestinal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Raludotatug Deruxtecan (R-DXd)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-17. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-11-12.